{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:23:00Z","timestamp":1791397380892,"version":"4.3.3"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bioorg.2023.106970","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T18:49:51Z","timestamp":1700074191000},"page":"106970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-127X","authenticated-orcid":false,"given":"Pengxing","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linna","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bioorg.2023.106970_b0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106970_b0010","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.bioorg.2023.106970_b0015","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106970_b0020","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jtho.2016.05.036","article-title":"ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study","volume":"11","author":"Reck","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"17","key":"10.1016\/j.bioorg.2023.106970_b0025","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.4161\/cbt.8.17.9205","article-title":"BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities","volume":"8","author":"Sun","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106970_b0030","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1177\/1947601911407324","article-title":"The genomics of lung adenocarcinoma: opportunities for targeted therapies","volume":"1","author":"Greulich","year":"2010","journal-title":"Genes Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106970_b0035","first-page":"67","article-title":"Standards for the diagnosis and treatment of primary lung cancer (2015 version) in China","volume":"37","author":"Zhi","year":"2015","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"14","key":"10.1016\/j.bioorg.2023.106970_b0040","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1021\/acs.jmedchem.5b00840","article-title":"Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer","volume":"59","author":"Song","year":"2016","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106970_b0045","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1021\/acs.jmedchem.7b01310","article-title":"Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2023.106970_b0050","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.bioorg.2023.106970_b0055","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106970_b0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.lungcan.2011.10.023","article-title":"Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies","volume":"76","author":"Tan","year":"2012","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.bioorg.2023.106970_b0065","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/nsmb.2168","article-title":"Mechanistic insights into the activation of oncogenic forms of EGF receptor","volume":"18","author":"Wang","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106970_b0070","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2012.02.063","article-title":"Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization","volume":"149","author":"Shan","year":"2012","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bioorg.2023.106970_b0075","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-07-2248","article-title":"Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"14","author":"Engelman","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106970_b0080","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106970_b0085","first-page":"1336","article-title":"BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors","volume":"9","author":"Minkovsky","year":"2008","journal-title":"Curr. Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.bioorg.2023.106970_b0090","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106970_b0095","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106970_b0100","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106970_b0105","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.bioorg.2023.106970_b0110","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR-mutated non-small-cell lung cancer","volume":"372","author":"Sequist","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106970_b0115","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1021\/acs.jmedchem.8b01823","article-title":"Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor","volume":"62","author":"Shi","year":"2019","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106970_b0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: First Global Approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.bioorg.2023.106970_b0125","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106970_b0130","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jtho.2015.12.093","article-title":"Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer","volume":"11","author":"Song","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"7605","key":"10.1016\/j.bioorg.2023.106970_b0135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106970_b0140","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.bbrc.2018.05.154","article-title":"Crystal structure of EGFR T790M\/C797S\/V948R in complex with EAI045","volume":"502","author":"Zhao","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"14","key":"10.1016\/j.bioorg.2023.106970_b0145","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106970_b0150","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov."},{"issue":"34","key":"10.1016\/j.bioorg.2023.106970_b0155","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106970_b0160","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2174\/1871520619666190313161009","article-title":"Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective","volume":"19","author":"Bao","year":"2019","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bioorg.2023.106970_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114533","article-title":"Recent advances in the development of EGFR degraders: PROTACs and LYTACs","volume":"239","author":"Hong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106970_b0170","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.apsb.2019.06.010","article-title":"Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor","volume":"9","author":"He","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2023.106970_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112388","article-title":"Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR(L858R\/T790M) NSCLCs by the conformation constrained strategy","volume":"199","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106970_b0180","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1021\/acs.jmedchem.0c02005","article-title":"Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer","volume":"64","author":"Meng","year":"2021","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2023.106970_b0185","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106970_b0190","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/acsmedchemlett.8b00161","article-title":"Meridianin D Analogues Display Antibiofilm Activity against MRSA and Increase Colistin Efficacy in Gram-Negative Bacteria","volume":"9","author":"Huggins","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2023.106970_b0195","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.9b01392","article-title":"Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor","volume":"63","author":"Su","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106970_b0200","doi-asserted-by":"crossref","first-page":"16786","DOI":"10.1002\/chem.201503474","article-title":"Through-Space 1,4-Palladium Migration and 1,2-Aryl Shift: Direct Access to Dibenzo[a, c]carbazoles through a Triple C-H Functionalization Cascade","volume":"21","author":"Bhunia","year":"2015","journal-title":"Chem. A Eur. J."},{"key":"10.1016\/j.bioorg.2023.106970_b0205","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1021\/acs.orglett.9b00739","article-title":"A Three-Component Strategy for Benzoselenophene Synthesis under Metal-Free Conditions Using Selenium Powder","volume":"21","author":"Ni","year":"2019","journal-title":"Org. Lett."},{"key":"10.1016\/j.bioorg.2023.106970_b0210","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.tet.2015.12.028","article-title":"Me2AlCl-mediated carboxylation, ethoxycarbonylation, and carbamoylation of indoles","volume":"72","author":"Nemoto","year":"2016","journal-title":"Tetrahedron"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106970_b0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/adsc.201801226","article-title":"Br\u00f8nsted acid-catalyzed direct C(sp2)\u2212H heteroarylation enabling the synthesis of structurally diverse biaryl derivatives","volume":"361","author":"Yuan","year":"2019","journal-title":"Adv. Synth. Catal."},{"key":"10.1016\/j.bioorg.2023.106970_b0220","doi-asserted-by":"crossref","DOI":"10.1002\/chem.201903464","article-title":"Palladium-catalyzed 'on-water' tandem cyclization reactions for the synthesis of biologically important 4-arylquinazolines","author":"Yuan","year":"2019","journal-title":"Chemistry"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106970_b0225","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1021\/acs.orglett.9b04241","article-title":"Palladium-catalyzed ligand-free double cyclization reactions for the synthesis of 3-(1'-Indolyl)-phthalides","volume":"22","author":"Yuan","year":"2020","journal-title":"Org. Lett."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106970_b0230","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106970_b0235","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.bioorg.2023.106970_b0240","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"216","key":"10.1016\/j.bioorg.2023.106970_b0245","doi-asserted-by":"crossref","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106970_b0250","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1535-7163.MCT-17-1033","article-title":"Pharmacological and structural characterizations of naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, EGFR-mutated non-small cell lung cancer","volume":"17","author":"Hirano","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"10.1016\/j.bioorg.2023.106970_b0255","first-page":"5749","article-title":"ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy","volume":"62","author":"Wakeling","year":"2002","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106970_b0260","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ajh\/hpaa066","article-title":"Icotinib attenuates monocrotaline-induced pulmonary hypertension by preventing pulmonary arterial smooth muscle cell dysfunction","volume":"33","author":"Peng","year":"2020","journal-title":"Am. J. Hypertens."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106970_b0265","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1111\/cas.14451","article-title":"Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M\/C797S mutation in non-small cell lung cancer","volume":"111","author":"Akazawa","year":"2020","journal-title":"Cancer Sci."},{"issue":"19","key":"10.1016\/j.bioorg.2023.106970_b0270","doi-asserted-by":"crossref","first-page":"14895","DOI":"10.1021\/acs.jmedchem.1c01452","article-title":"Discovery of new 4-indolyl quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors","volume":"64","author":"Yuan","year":"2021","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2023.106970_b0275","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1080\/15384101.2020.1852756","article-title":"Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer","volume":"19","author":"Hu","year":"2020","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106970_b0280","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1186\/s12885-020-07667-7","article-title":"EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells","volume":"20","author":"Gong","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2023.106970_b0285","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/bj2590577","article-title":"Epidermal-growth-factor-stimulated phosphorylation of calpactin II in membrane vesicles shed from cultured A-431 cells","volume":"259","author":"Blay","year":"1989","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106970_b0290","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.3892\/ol.2017.6591","article-title":"Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors","volume":"14","author":"Hamamoto","year":"2017","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2023.106970_b0295","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/dmd.119.087684","article-title":"Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 transporters: an important role in transplacental pharmacokinetics","volume":"47","author":"Tupova","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106970_b0300","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00204-019-02417-6","article-title":"Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen","volume":"93","author":"Windt","year":"2019","journal-title":"Arch. Toxicol."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106970_b0305","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41419-023-06238-5","article-title":"Inhibition of LSD1 induces ferroptosis through the ATF4-xCT pathway and shows enhanced anti-tumor effects with ferroptosis inducers in NSCLC","volume":"14","author":"Du","year":"2023","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106970_b0310","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.gendis.2022.11.002","article-title":"Inhibition of lysine-specific demethylase 1 (LSD1) prevented tumor growth and metastasis by downregulating PD-L1 expression in lung adenocarcinoma","volume":"10","author":"He","year":"2023","journal-title":"Genes Dis."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823006314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823006314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:51:29Z","timestamp":1758617489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823006314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":62,"alternative-id":["S0045206823006314"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106970","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106970"}}